Elegrobart Biosimilar Monoclonal Antibody for Research

Cat No.: GMP-Bios-INN-1172

Anti-TBC therapeutic antibody (Pre-made Elegrobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Elegrobart (development codes VRDN-003/ZL-1109) is a monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF1R). It is developed by Viridian Therapeutics for thyroid eye disease. It is in Phase III clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1172-1mg 1mg 3090
GMP-Bios-INN-1172-10mg 10mg
GMP-Bios-INN-1172-100mg 100mg
GMP-Bios-INN-1172-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Elegrobart biosimilar, Whole mAb: Anti-TBC therapeutic antibody
INN Name Elegrobart
Target TBC
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC